

RESEARCH ARTICLE

Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma

Xin-En Huang^{1*}, Guang-Yu Tian², Jie Cao¹, Xia Xu¹, Yan-Yan Lu¹, Xue-Yan Wu¹, Jin Liu¹, Lin Shi¹, Jin Xiang³

Abstract

Purpose: The current research was conducted to investigate the efficacy and safety of pemetrexed given continuously as a basement agent for first-, second- to third line chemotherapy of patients with metastatic lung adenocarcinoma. **Patients and Methods:** Patients with metastatic lung adenocarcinoma who were diagnosed in Jiangsu Cancer Hospital and Research Institute, were enrolled. All received pemetrexed 500 mg/m² (intravenous; on day 1), and another chemotherapeutic agent every 3 weeks until disease progression, or intolerable toxicity. Then the patients were changed to a second line chemotherapy that was still based on pemetrexed 500 mg/m² and another chemotherapeutic agent differing from the first line example, until disease progression, or intolerable toxicity. When third line chemotherapy was needed, pemetrexed 500 mg/m² and another new chemotherapeutic agent were combined until disease progression. Evaluation of efficacy was conducted after two cycles of chemotherapy using the Response Evaluation Criteria for Solid Tumors. Toxicity was recorded according to NCI Criteria for Adverse Events version 3.0. **Results:** From January 2010 to September 2013, 15 patients were enrolled. Their median age was 56 years (range 43 to 77 years). Eight patients were male and 7 female. Five patients (33.3%) achieved PR, while 6 patients (40.0%) remained stable, no CR on first line; and 1 PR (7.7%), 5 stable (38.5%) were recorded when pemetrexed was ordered in second line; 5 patients (41.7%) were stable after pemetrexed was combined in third line; no complete response was observed. Main side effects were grade 1 to 2 neutrophil suppression and thrombocytopenia. Other toxicities included elevated transaminase and oral mucositis, but no treatment related death occurred. **Conclusions:** Pemetrexed continuously as a basement agent from first-, second- to third line chemotherapy is mildly effective in treating patients with metastatic lung adenocarcinoma with tolerable toxicity.

Keywords: Pemetrexed - lung adenocarcinoma - first-third line therapies - toxicity - efficacy

Asian Pac J Cancer Prev, 14 (11), 6663-6667

Introduction

Cisplatin-based chemotherapy for patients with advanced NSCLC results in mild improvement in survival, as compared with supportive care. Combination of a platinum from first-, second- to third line therapy plus another chemotherapeutic agent continues to be a standard of care (Marino et al., 1994). However, side effects of platinum is also significant, e.g., nausea, vomiting, and renal toxicity, and is the reason of discontinuation of chemotherapy. On this background, we consider that cisplatin could be recommended as a component of first line chemotherapy (NCCN guideline, 2013), but if failed, should not continuously be a component of second- and even third-

line agent in treating patients with lung adenocarcinoma.

Pemetrexed (PEM) is an effective and well tolerated chemotherapeutic agent. Based on previous studies, it is considered that PEM is proper for patients who were pathologically diagnosed with lung adenocarcinoma (Rodrigues-Pereira et al., 2011). The tolerability of PEM is good, thus is recommended for patients with advanced NSCLC and adenocarcinoma, regardless of whether TS, GARFT, and DHFR is over-expressed. Considering general characteristics of patients with advanced NSCLC and the pharmacokinetics and well tolerability of PEM, we hypothesize that pemetrexed as a component of first-, second- and third line chemotherapy could be a reasonable regimen in treating patients with lung adenocarcinoma.

¹Department of Chemotherapy, ³Department of Research, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research, Nanjing, ²Department of Oncology, JiangDu People's Hospital of Yangzhou, Yangzhou, Jiangsu, China *For correspondence: huangxinen06@aliyun.com

Materials and Methods

Patient eligibility

Eligible patients should be histologically confirmed adenocarcinoma of lung with clinical evidence of metastatic disease. Other eligible criteria include: age ≥ 18 years; adequate bone marrow (platelets $\geq 100 \times 10^9$ cells/l, absolute neutrophil count $\geq 1.5 \times 10^9$ cells/l), hepatic (total bilirubin $\leq 2 \times$ the upper limit of normal; aspartate aminotransferase $\leq 3 \times$ the upper limit of normal or $\leq 5 \times$ the upper limit of normal if metastatic disease was present in the liver) and calculated creatinine clearance ≥ 45 ml/min, using the modified Cockcroft and Gault calculated creatinine clearance formula; a life expectancy of ≥ 3 months; sign an informed consent before chemotherapy. Complete patient histories, physical examinations, complete blood cell counts, chemistries (aspartate aminotransferase, total bilirubin, creatinine, albumin), calculated creatinine clearance were performed at baseline prior to each course of treatment. Complete blood cell count was repeated weekly. Radiological studies (roentgenograms, computed axial tomographic scans or magnetic resonance imaging) were performed at baseline and after every two cycles of therapy to assess tumor response. CR was defined as complete disappearance of all measurable disease. Partial response (PR) was defined as at least 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. Progression was defined as 50% increase or an increase of 10 cm² (whichever is smaller) in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) or appearance of any new lesion, or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). Stable disease (SD) was documented when there was persistence of disease without meeting the criteria for progression, PR or CR.

Treatment

Pemetrexed 500 mg/m² was given intravenously on day 1, premedication was conducted, and repeated every 3 weeks: 400 μ g of folic acid was given orally daily and 1000 μ g of vitamin B12 was given intramuscularly every 9 weeks starting 7 days prior to the first dose and until 3 weeks after the last dose of pemetrexed; 4.5 mg of dexamethasone was given orally every 12 h on the day before, day of and the day after pemetrexed; and another chemotherapeutic agent (e.g., a platinum, paclitaxel, docetaxel, ifosfamide, irinotecan, etoposide, etc.) every 3 weeks until disease progression, or intolerable toxicity. Then, the patients were changed to second line chemotherapy that was based on pemetrexed 500 mg/m² and another chemotherapeutic agent different from the first line until disease progression, or intolerable toxicity. When third line chemotherapy was needed, pemetrexed 500 mg/m² and a chemotherapeutic agent different from first and second line was combined until disease progression. Antiemetics were given with chemotherapy on days 1. All toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (version 2.0) (National Cancer Institute, 1998).

Table 1. General Characteristics of Patients (n=15)

Characteristic	Patients, n (%)
Age, years	
Median	56
Range	43-77
Sex	
Male	8 (53%)
Female	7 (47%)
ECOG performance status	
≤ 2	13 (87%)
> 2	2 (13%)
Number of organs involved	
1	7 (53%)
≥ 2	8 (47%)
Sites of metastases	
Lymph node	10 (33%)
Liver	0 (0%)
Lung	6 (20%)
Bone	9 (30%)
Others	5 (17%)
Pemetrexed based Chemotherapy	
First line	15
Second line	13
Third line	12

ECOG, Eastern Cooperative Oncology Group

Table 2. Chemotherapy

Chemotherapy
First Line Chemotherapy
PEM (500 mg/m ²) d1+DDP (20 mg/m ²) d1-5
PEM (500 mg/m ²) d1+CBP (300 mg/m ²) d2
Second line Chemotherapy
PEM (500 mg/m ²) d1+Decetaxel (40 mg/m ²) d1,8
PEM (500 mg/m ²) d1+Ifosfamide (1-1.5 g/m ²) d1-3 and d8-9
Third line Chemotherapy
PEM (500 mg/m ²)d1+CPT-11 (80 mg/m ²) d1,8
PEM (500 mg/m ²)d1+ lobaplatin (30 mg/m ²) d2

PEM, Pemetrexed

Research experience

We have enough experience in conducting medical researches, and have published some results elsewhere (Huang et al., 2011; Li et al., 2011; Li et al., 2011; Li et al., 2011; Xu et al., 2011; Xu et al., 2011; Xu et al., 2011; Yan et al., 2011; Zhang et al., 2011; Gong et al., 2012; Liu et al., 2012; Gu et al., 2013; Li et al., 2012; Shu et al., 2012; Zhan et al., 2012; Zhan et al., 2012; Xu et al., 2012; Xu et al., 2012; Yu et al., 2012; Zhang, et al., 2012; Zhang et al., 2012; Chen et al., 2013; Dai et al., 2013; Deng et al., 2013; Huang et al., 2013; Liu et al., 2013; Liu et al., 2013; Liu et al., 2013; Lu et al., 2013; Sun et al., 2013; Wei et al., 2013; Wu et al., 2013; Yang et al., 2013; Yin et al., 2013; Yin et al., 2013).

Results

Patients

A total of 15 patients were enrolled from January 2010 to September 2013. All patients received at least one systemic chemotherapy. All patients had adenocarcinoma of the lung. General characteristics of patients were listed in Table 1. Fifteen patients received pemetrexed based

Table 3. Common Grade 1 to 4 Toxicities^a

Type	Haematological Toxicities	None-Haematological Toxicities
Grade 1	2	3
Grade 2	9	4
Grade 3	2	2
Grade 4	0	0

^aToxicity graded according to National Cancer Institute Common Toxicity Criteria

combination therapy as first line, 13 as second, and 12 as third line chemotherapy (Table 2).

Efficacy

Fifteen patients completed at least 2 cycles of chemotherapy on first line chemotherapy, and were evaluated according to study protocol. Overall, 5 patients (33.3%) achieved PR, while 6 patients (40.0%) remained stable, no CR on first line; and 1 PR (7.7%), 5 stable (38.5%) were recorded when pemetrexed was ordered in second line; 5 patients (41.7%) got stable after pemetrexed was combined in third line; no complete response was observed (Table 2).

Toxicity

Main side effects were grade 1 to 2 neutrophil suppression and thrombocytopenia. Other toxicities included elevated transaminase and oral mucositis, no treatment related death occurred (Table 3).

Discussion

According to WHO statistics, the incidence and mortality rate of lung cancer increases year by year. And in China, more than 75% of patients with non-small cell lung cancer (NSCLC) present with locally advanced (stage IIIB) or metastatic (stage IV) disease at diagnosis (Zhou et al., 2011). For patients in this setting, platinum-based chemotherapy is recommended as first-line treatment according to current guideline (Pfister et al., 2003). Some studies showed non-inferior efficacy and better tolerability for PEM plus cisplatin compared with cisplatin plus other chemotherapeutic agents eg. gemcitabine or docetaxel especially for patients with adenocarcinoma (Reck et al., 2009; Scagliotti et al., 2009; Klein et al., 2010). PEM is an antifolate that inhibits multiple enzymes involved in purine and pyrimidine synthesis. The mechanism of action consists of the inhibition of three key enzymes in the folate metabolic pathway, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT) (Giovannetti et al., 2005). This mechanism leads to depletion of fully reduced folate, ultimately resulting in disruption of nucleotide synthesis for both pyrimidines and purines. Pemetrexed, once in the cell, is an excellent substrate for polyglutamate synthetase, leading to extensive intracellular polyglutamate derivatives that are more potent inhibitors of the described enzymes. Polyglutamated pemetrexed is retained intracellularly longer than the parent compound, resulting in more prolonged cytotoxic

effects (Esteban et al., 2009). It is reported that resistance to PEM is correlated with high pre-treatment TS, GARFT, and DHFR expression in NSCLC cell (Eismann et al., 2006). TS expression is regarded as the most meaningful predictor for sensitivity or resistance to PEM in fresh tumor tissue. But for patients with advanced NSCLC, no enough tumor tissue is available for the detection of TS, GARFT, and DHFR expression. And limited by the condition of experiment in different hospitals and regions, the test result cannot be in full compliance with the actual situation. Thus at present, PEM is given to patients with advanced NSCLC, regardless of whether TS, GARFT, and DHFR is over-expressed. And in the field of maintenance therapy for advanced NSCLC, in line with the evidence currently available, it represents a treatment option. In real practice, maintenance therapy is recommended to patients without disease progression or persistent chemotherapy-induced toxicities after several cycles of first-line chemotherapy, however, with good performance status. Two different strategies (switch or continuation maintenance) are available. The hazard ratio for PFS is in the range of 0.6 to 0.7 in most of the trials for both strategies. OS is only significantly improved in the SATURN (Cappuzzo et al., 2010) and JMEN (Ciuleanu et al., 2009) switch-maintenance trials, and in the PARAMOUNT trial (Paz-Ares et al., 2012) with the continuation strategy. These were the only three trials with a reasonable size (539 to 889 patients) to enable adequately powered comparisons. No powered comparative trials of maintenance with different chemotherapy drugs or targeted agents have been conducted, thus, no conclusive data are available yet about the potential advantage of any given therapy. The potential advantages and disadvantages, including toxicities, of continuation or switch maintenance is not sure. The PARAMOUNT trial revealed that pemetrexed maintenance therapy could improve efficacy over placebo following four courses of cisplatin/pemetrexed (Paz-Ares et al., 2011). The primary objective of this study, PFS, was improved in the pemetrexed maintenance arm compared with placebo (4.1 vs. 2.8 months, HR 0.62), and OS was also significantly improved (13.9 vs. 11 months, HR 0.78) (Paz-Ares et al., 2012).

Recent placebo-controlled trials evaluated the role of pemetrexed as maintenance therapy for patients with advanced NSCLC following disease control with four cycles of platinum-based therapy and suggested that pemetrexed maintenance significantly improved PFS (4.0 vs. 2.0 months; HR 0.60) and OS (13.4 vs. 10.6 months; HR 0.79) (Ciuleanu et al., 2009; Cappuzzo et al., 2010). Prolonging treatment duration has shown to prolong PFS, without a clinically significant effect on survival, at the cost of relevant toxicity, particularly with platinum agents and taxanes (Lima et al., 2009). This is the reason why we try to develop a regimen that is tolerable to patient at this point. However, no study focused on pemetrexed as a basement of combined treatment from first to second and third line chemotherapy. Our study demonstrated that 5 patients (33.3%) achieved PR, while 6 patients (40.0%) remained stable, on first line; and 1 PR (7.7%), 5 stable (38.5%) were recorded when pemetrexed was ordered in second line; 5 patients (41.7%) got stable after pemetrexed

was combined in third line. Main side effects were Grade 1 to 2 neutrophil suppression and thrombocytopenia. Other toxicities included elevated transaminase and oral mucositis, no treatment related death occurred.

In conclusion, our study suggested that pemetrexed continuously as a basement agent from first-, second- to third line chemotherapy is mildly effective in treating patients with metastatic lung adenocarcinoma with tolerable toxicity.

Acknowledgements

Dr. Xin-En Huang is supported in part by a grant from Jiangsu Provincial Administration of Traditional Chinese Medicine (LZ11091), and in part from a special research fund from Organization Department of Jiangsu Provincial Party Committee, Talent Work Leading Group of Jiangsu Province (333 High-level Personnel Training Project).

References

Adjei AA (2004). Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. *Clin Cancer Res*, **10**, S4276-80.

Ajani JA (2005). Evolving chemotherapy for advanced gastric cancer. *Oncologist*, **10**, 49-58.

Bajetta E, Celio L, Buzzoni R, et al (2003). Phase II study of pemetrexed disodium (alimta) administered with oral folic acid in patients with advanced gastric cancer. *Ann Oncol*, **14**, 1543-8.

Celio L, Buzzoni R, Longarini R, et al (2002). Pemetrexed in gastric cancer: clinical experience and future perspectives. *Semin Oncol*, **29**, 63-8.

Celio L, Sternberg CN, Labianca R, et al (2009). Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. *Ann Oncol*, **20**, 1062-7.

Chen JS, Chao Y, Bang YJ et al (2010). A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. *Anticancer Drugs*, **21**, 777-84.

Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of Loubolaplatin (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. *Asian Pac J Cancer Prev*, **14**, 413-7.

Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. *Asian Pac J Cancer Prev*, **12**, 77-80.

Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. *Asian Pac J Cancer Prev*, **13**, 873-5.

Gu M, Li SY, Huang XE, et al (2013). A phase II study on continuous infusion paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. *Asian Pac J Cancer Prev*, **13**, 5587-91.

Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. *Asian Pac J Cancer Prev*, **12**, 2797-800.

Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. *Asian Pac J Cancer Prev*, **14**, 2611-4.

Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. *Asian Pac J Cancer Prev*, **11**, 1059-62.

Karpeh MS, Kelsen DP, Tepper JE (2001). Cancer of the stomach. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): *Cancer: Principles and Practice of Oncology*, 6th edition. Philadelphia, PA: Lippincott, Williams and Wilkins, 1092-126.

Kim JH, Lee KW, Jung Y, et al (2005). Cytotoxic effects of pemetrexed in lung adenocarcinoma cells. *Cancer Sci*, **96**, 365-71.

Kim YH, Chung HC, Kang WK, et al (2008). Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. *Cancer Chemother Pharmacol*, **62**, 263-70.

Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin administered by rectal route in treating cancer related pain. *Asian Pac J Cancer Prev*, **12**, 2477-8.

Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. *Asian Pac J Cancer Prev*, **13**, 301-4.

Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. *Asian Pac J Cancer Prev*, **12**, 487-90.

Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. *Asian Pac J Cancer Prev*, **12**, 2405-09.

Liu J, Huang XE, Tian GY, et al (2013). Phase II study on safety and efficacy of Yadanzi® (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. *Asian Pac J Cancer Prev*, **14**, 2009-12.

Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from *Rosa roxburghii* Tratt and *Fagopyrum cymosum*. *Asian Pac J Cancer Prev*, **13**, 2409-14.

Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non-small cell lung cancer. *Asian Pac J Cancer Prev*, **14**, 2663-5.

Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. *Asian Pac J Cancer Prev*, **14**, 2005-8.

Martin M (2006). Clinical experience with pemetrexed in breast cancer. *Semin Oncol*, **33**, S15-8.

Ohtsu A (2008). Chemotherapy for metastatic gastric cancer: past, present, and future. *J Gastroenterol*, **43**, 256-64.

Parkin DM, Bray F, Ferlay J et al (2005). Global cancer statistics, 2002. *CA Cancer J Clin*, **55**, 74-108.

Parkin DM, Bray FI, Devesa SS (2001). Cancer burden in the year 2000. The global picture. *Eur J Cancer*, **37**, S4-66.

Paz-Ares LG, de Marinis F, Dediu M, et al (2011). PARAMOUNT: phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. *J Clin Oncol*, **29** (suppl; abstr CRA7510).

Paz-Ares L, de Marinis F, Dediu M, et al (2012). Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). *J Clin Oncol*, **30** (suppl; abstr LBA7507).

- Pozzo C, Barone C (2008). Is there an optimal chemotherapy regimen for the treatment of advanced lung adenocarcinoma that will provide a platform for the introduction of new biological agents? *Oncologist*, **13**, 794-806.
- Rollins KD, Lindley C (2005). Pemetrexed: a multitargeted antifolate. *Clin Ther*, **27**, 1343-82.
- Ross P, Nicolson M, Cunningham D, et al (2002). Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *J Clin Oncol*, **20**, 1996-2004.
- Shu J, Li CG, Liu YC, et al (2012). Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. *Asian Pac J Cancer Prev*, **13**, 2399-403.
- Sun MQ, Meng AF, Huang XE, et al (2013). Comparison of psychological influence on breast cancer patients between breast-conserving surgery and modified radical mastectomy. *Asian Pac J Cancer Prev*, **14**, 149-52.
- Sun MQ, Meng AF, Huang XE, et al (2013). Comparison of psychological influence on breast cancer patients between breast-conserving surgery and modified radical mastectomy. *Asian Pac J Cancer Prev*, **14**(1):149-52.
- Wagner AD, Unverzagt S, Grothe W, et al (2010). Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev*, **3**:CD004064.
- Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. *Asian Pac J Cancer Prev*, **14**, 2019-22.
- Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. *Asian Pac J Cancer Prev*, **12**, 2233-6.
- Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar combined with chemotherapy in advanced colorectal cancer patients. *Asian Pac J Cancer Prev*, **12**, 3087-90.
- Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced lung adenocarcinoma cases. *Asian Pac J Cancer Prev*, **12**, 985-7.
- Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. *Asian Pac J Cancer Prev*, **13**, 2349-54.
- Xu X, Wang L, Xu HQ, Huang XE, et al (2013). Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. *Asian Pac J Cancer Prev*, **14**, 2591-4.
- Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. *Asian Pac J Cancer Prev*, **11**, 1115-8.
- Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. *Asian Pac J Cancer Prev*, **12**, 2291-4.
- Yin HT, Tian QZ, Guan L, et al (2011). In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. *Asian Pac J Cancer Prev*, **14**, 1703-6.
- Yin HT, Zhang DG, Wu XL, Huang XE, Chen G (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. *Asian Pac J Cancer Prev*, **14**, 409-12.
- Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. *Asian Pac J Cancer Prev*, **13**, 2339-40.
- Zhan YP, Huang XE, Cao J, et al (2012). Clinical study on safety and efficacy of Quinin (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. *Asian Pac J Cancer Prev*, **13**, 4773-6.
- Zhan YP, Huang XE, Cao J (2012). Clinical safety and efficacy of Kanglaite (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. *Asian Pac J Cancer Prev*, **13**, 5319-21.
- Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. *Asian Pac J Cancer Prev*, **12**, 81-5.
- Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II Study on Voriconazole in Treating Chinese Patients with Malignant Hematological Disorder and Invasive Aspergillosis. *Asian Pac J Cancer Prev*, **13**, 2415-8.
- Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. *Asian Pac J Cancer Prev*, **10**, 1147-50.